Type of malignancy - Non-small cell lung cancer (squamous cell carcinoma at higher risk than non-squamous cell carcinoma of the lung)
- Renal cell carcinoma
|
ICI regimen - Combination immunotherapy (eg, CTLA-4 inhibitor plus PD-L1 inhibitor) carries a higher risk than single-agent immunotherapy (eg, PD-1 or PD-L1 inhibitors)
|
Pre-existing interstitial lung abnormality or confirmed interstitial lung disease |
Chronic lung disease (eg, chronic obstructive pulmonary disease, asthma) |
Smoking or tobacco use |
Autoimmune disease |
Prior curative-intent radiation therapy to the lungs |
Male sex |